The plasma fractionation industry is anticipated to achieve a valuation of approximately US$ 40,731.98 million by the year 2028, rising from US$ 26,575.83 million in 2021. This growth trajectory indicates a compound annual growth rate (CAGR) of 6.3% from 2021 to 2028. The primary drivers of this market expansion include the increasing utilization of plasma therapy and the proactive involvement of companies in advancing market initiatives. Nonetheless, the presence of recombinant or non-plasma alternatives poses a challenge. Additionally, the potential for development in emerging markets presents attractive opportunities for the plasma fractionation sector.
As highlighted in the previous section, the market presents significant opportunities for businesses engaged in related activities. The favorable growth trends are prompting both global and regional players to implement a mix of organic and inorganic growth strategies. Consequently, this is likely to draw more substantial investments into the market throughout the forecast period. Below are some notable developments and initiatives undertaken by key market participants.
- In March 2021, Grifols, S.A., a prominent player in the plasma sector, acquired approximately 25 plasma collection centers located in the United States from Bio Products Laboratory Holdings Limited. This acquisition is projected to contribute an additional one million liters of plasma for fractionation purposes.
- In August 2021, Biotest AG inaugurated its sixth plasma collection facility in the Czech Republic, having received the necessary operating license from the national public health authority, SUKL. This modern center features around 15 donor beds and offers amenities such as television and Wi-Fi for donors. It operates six days a week for twelve hours each day.
- In February 2020, Advent International Corporation, a global private equity firm based in the United States, acquired a majority interest in Bharat Serums and Vaccines. This investment is anticipated to enhance and broaden Bharat Serums' product offerings in both domestic and international markets.
The plasma fractionation market is categorized by application into several segments, including neurology, immunology, hematology, critical care, pulmonology, and others. The neurology segment is projected to dominate the market share in 2021 and is expected to exhibit the highest CAGR during the forecast period. Furthermore, the market is segmented by product into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and various other plasma products. The immunoglobulin segment is forecasted to capture the largest market share in 2021 and is also expected to experience the highest growth rate from 2021 to 2028.
Key secondary sources utilized in the preparation of the report on the global plasma fractionation market include the Food Safety and Inspection Service, the Food and Drug Administration, and the European Medical Association.